Summary
A research overview of CJC-1295 dosage protocols, mechanism of action as a GHRH analogue, study findings on growth hormone secretion, and how it is studied in combination with Ipamorelin in pulsatile GH research.
What is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), a 44-amino acid peptide produced in the hypothalamus that stimulates the pituitary gland to synthesise and release growth hormone (GH).
Natural GHRH has a very short half-life in circulation -- approximately 7 minutes -- because it is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV) enzymes. CJC-1295 was developed to address this limitation through structural modifications that resist DPP-IV cleavage and, in its DAC variant, through conjugation to a Drug Affinity Complex that binds serum albumin and extends the peptide's circulating life to 6-8 days.
Two distinct variants exist in the research literature, and the distinction is important for understanding dosage protocols:
CJC-1295 with DAC: The version with Drug Affinity Complex modification. Half-life of 6-8 days. Produces a prolonged, sustained elevation in baseline GH levels. Dosed once or twice weekly in research protocols.
CJC-1295 without DAC (Modified GRF 1-29, Mod GRF): Lacks the albumin-binding modification. Half-life of approximately 30 minutes, similar to native GHRH. Produces a more physiological pulsatile GH release pattern when dosed multiple times daily.
Mechanism of Action: How CJC-1295 Works
CJC-1295 acts on the growth hormone-releasing hormone receptor (GHRHR) located on somatotroph cells in the anterior pituitary gland. Activation of this receptor triggers a cAMP-mediated signalling cascade that increases GH synthesis and promotes GH release into circulation.
The downstream effects of elevated GH studied in research include:
IGF-1 Production: GH stimulates the liver to produce insulin-like growth factor 1 (IGF-1), the primary mediator of GH's anabolic and growth-promoting effects on peripheral tissues.
Protein Synthesis: Elevated GH and IGF-1 signalling is associated with increased protein synthesis in muscle and connective tissue in preclinical and clinical models.
Fat Metabolism: GH promotes lipolysis (fat breakdown) particularly in visceral adipose tissue. This effect is the basis for tesamorelin's approval for HIV-associated lipodystrophy, where visceral fat accumulation is a primary concern.
Bone Turnover: GH and IGF-1 signalling influences bone formation and remodelling markers, studied in the context of skeletal health research.
The key distinction between CJC-1295 and direct GH administration in research is that CJC-1295 stimulates the pituitary to release its own GH, preserving the natural pulsatile rhythm of GH secretion and the feedback mechanisms that regulate it. Direct GH administration bypasses pituitary regulation entirely.
Published Clinical Research: Teichman et al. (2006)
The primary published clinical investigation of CJC-1295 with DAC is the dose-escalation study by Teichman et al., published in the Journal of Clinical Endocrinology and Metabolism in 2006. This study remains the foundational reference for CJC-1295 dosage protocols in the research community.
Study Design: Randomised, placebo-controlled dose escalation trial. Participants received single subcutaneous injections of CJC-1295 at four dose levels: 30, 60, 120, and 250 mcg/kg body weight.
Key Findings:
- Dose-dependent increases in mean plasma GH concentration across all dose levels
- The 250 mcg/kg dose produced a 2- to 10-fold increase in mean 24-hour GH concentration
- Sustained elevation of IGF-1 levels lasting 9-11 days following a single injection
- Half-life of CJC-1295 measured at 5.8-8.1 days across dose groups
- The prolonged IGF-1 elevation was described as a "GH wave" effect, suggesting potential for less frequent dosing
Adverse Events: Water retention was the most commonly reported adverse event, particularly at higher dose levels. Flushing and dizziness were also reported in a subset of participants. No serious adverse events were attributed to the study compound.
The study concluded that CJC-1295 produced prolonged, dose-dependent increases in GH and IGF-1 levels consistent with the intended pharmacological mechanism.
CJC-1295 Dosage Protocols in Current Research
Research protocols for CJC-1295 have evolved based on the half-life distinction between the two variants. The following protocols represent approaches documented in published and community research:
CJC-1295 with DAC Protocol
The long half-life of CJC-1295 with DAC supports infrequent dosing:
Standard research dosing: 1-2 mg (1000-2000 mcg) administered subcutaneously once weekly or once every two weeks.
Rationale: The albumin-binding mechanism produces sustained GH elevation between doses. More frequent dosing risks accumulation and continuous (rather than pulsatile) GH elevation, which may have different biological implications than physiological pulsatile patterns.
Research observation: Continuous GH elevation, as produced by high-frequency CJC-1295 with DAC dosing, may downregulate somatotroph sensitivity over time. Research protocols typically space doses to allow partial normalisation before the next administration.
CJC-1295 without DAC Protocol (Modified GRF 1-29)
The short half-life of the no-DAC variant requires more frequent dosing to maintain research-relevant GH elevations:
Standard research dosing: 100-200 mcg administered subcutaneously 2-3 times daily, typically timed around sleep and training sessions.
Rationale: This protocol attempts to mimic the natural pulsatile GH release pattern, with peaks occurring at approximately 3-4 hour intervals. The no-DAC variant produces discrete GH pulses rather than sustained elevation.
Timing consideration: Research protocols often place at least one daily dose at or near sleep onset, given that the largest natural GH pulse occurs during slow-wave sleep in physiological conditions.
CJC-1295 and Ipamorelin: The Combined Research Protocol
The most commonly researched CJC-1295 protocol involves combination with Ipamorelin, a selective growth hormone secretagogue that works through a different receptor.
Why the combination is studied: CJC-1295 and Ipamorelin target distinct but complementary pathways in GH regulation:
- CJC-1295 activates the GHRH receptor, stimulating GH synthesis and promoting GH release
- Ipamorelin activates the ghrelin receptor (growth hormone secretagogue receptor, GHSR), triggering GH release through a separate signalling pathway
When administered together, these compounds appear to produce synergistic GH release -- greater than the sum of either compound administered alone. This synergy is attributed to simultaneous activation of both the "accelerator" (GHRH receptor) and the "trigger" (GHSR) in pituitary GH secretion.
Selectivity advantage of Ipamorelin: Compared to older growth hormone releasing peptides (GHRPs) such as GHRP-2 and GHRP-6, Ipamorelin shows high selectivity for GH release without significant elevation of cortisol or prolactin. This selectivity profile makes it the preferred GHSR agonist in research protocols designed to study GH-specific effects.
BioPepTech supplies Ipamorelin Pen (Flow) with same-day delivery across Bali, pre-filled and verified to >=99% purity.
See the full research overview: Ipamorelin and CJC-1295: Growth Hormone Peptide Research
CJC-1295 vs Tesamorelin: How Do the GHRH Analogues Compare?
Tesamorelin is a different GHRH analogue that has received FDA approval for HIV-associated lipodystrophy. It represents the only GHRH analogue with clinical approval as of 2026, making its pharmacological profile particularly well-documented.
| CJC-1295 (with DAC) | Tesamorelin | |
|---|---|---|
| Mechanism | GHRH receptor agonist | GHRH receptor agonist |
| Half-life | 6-8 days (with DAC) | ~26 minutes |
| Dosing frequency | Once or twice weekly | Once daily |
| Approval | Research compound | Approved (Egrifta) |
| Primary research focus | GH/IGF-1 elevation | Visceral adipose tissue |
Tesamorelin's once-daily dosing and extensive clinical data from HIV-lipodystrophy trials make it a reference compound for GHRH analogue research. CJC-1295 with DAC offers the practical advantage of less frequent administration.
BioPepTech supplies Tesamorelin Pen (Ignite) for researchers interested in GHRH analogue comparisons.
Research Considerations: Pulsatile vs Continuous GH Release
A key debate in growth hormone secretagogue research is whether pulsatile GH release (mimicking physiological patterns) produces different outcomes than continuous elevation.
Natural GH secretion is highly pulsatile: multiple distinct peaks occur over 24 hours, with the largest pulse occurring during deep sleep. Between pulses, GH levels approach undetectable concentrations. This pulsatile pattern appears important for maintaining pituitary receptor sensitivity and preventing GH resistance.
CJC-1295 with DAC criticism: The sustained GH elevation produced by weekly dosing does not replicate physiological pulsatility. Some researchers argue this distinction has practical significance for IGF-1 response and downstream receptor sensitivity over extended protocols.
Modified GRF 1-29 (no DAC) argument: The shorter half-life variant, when dosed 2-3 times daily with appropriate spacing, produces discrete GH pulses that more closely approximate physiological patterns. Proponents argue this offers a more physiologically appropriate research model.
Practical resolution in research protocols: Many researchers use a hybrid approach, using CJC-1295 no-DAC (Modified GRF 1-29) combined with Ipamorelin at 2-3 times daily dosing specifically to preserve the pulsatile pattern, reserving CJC-1295 with DAC for protocols where dosing convenience outweighs the pulsatility consideration.
Source Research-Grade Growth Hormone Peptides in Bali
BioPepTech supplies research-grade growth hormone secretagogues with same-day delivery across Bali, verified to >=99% purity with full Certificate of Analysis documentation.
- Ipamorelin Pen (Flow) -- Selective GHSR agonist, pre-filled, same-day delivery
- Tesamorelin Pen (Ignite) -- GHRH analogue with FDA approval history, pre-filled, same-day delivery
Free expert consultation for protocol guidance ->
Frequently Asked Questions
What dose of CJC-1295 is used in research?
The Teichman et al. (2006) clinical study used doses of 30, 60, 120, and 250 mcg/kg body weight as single injections. Contemporary research protocols for the with-DAC variant typically use 1-2 mg once or twice weekly. The no-DAC variant is typically studied at 100-200 mcg 2-3 times daily.
How long do CJC-1295 research protocols typically run?
Research protocols in the published and community literature typically range from 8 to 24 weeks, with longer protocols studied for cumulative IGF-1 and body composition effects. Shorter protocols are used for pharmacokinetic and dose-finding research.
Can CJC-1295 be studied without Ipamorelin?
Yes. CJC-1295 was validated as a standalone compound in the Teichman et al. clinical trial. The combination with Ipamorelin is a research design choice based on the synergistic GH release hypothesis, not a requirement.
What is Modified GRF 1-29?
Modified GRF 1-29 is another name for CJC-1295 without DAC. "GRF" stands for Growth hormone Releasing Factor. "Modified" refers to the DPP-IV resistance modifications present in CJC-1295 but not in natural GHRH. "1-29" refers to the first 29 amino acids of GHRH, which is the biologically active fragment.
Is CJC-1295 detectable in drug tests?
CJC-1295 is listed on the World Anti-Doping Agency (WADA) prohibited list as a peptide hormone in competitive sports contexts. Researchers should be aware of the relevant regulatory frameworks in their sport or jurisdiction.
Does CJC-1295 affect insulin sensitivity?
Growth hormone is known to have insulin-antagonistic effects at higher concentrations. Research protocols investigating GH secretagogues in metabolic contexts typically monitor glucose metabolism markers. This is particularly relevant in extended research protocols with frequent dosing.
What is the difference between CJC-1295 and sermorelin?
Sermorelin is an earlier synthetic GHRH analogue corresponding to the first 29 amino acids of native GHRH without the DPP-IV resistance modifications present in CJC-1295. Sermorelin has a shorter half-life and less potency than CJC-1295. CJC-1295 (especially the with-DAC variant) is considered a significant advancement over sermorelin in terms of duration and potency per dose.
References
Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006.
Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998.
Sackmann-Sala L et al. Activation of the GH/IGF-1 axis by CJC-1295. Journal of Endocrinology. Published experimental data.
Popovic V et al. Growth hormone secretion in the context of GHRH and GHRP research. Growth Hormone and IGF Research. Published review.
PubMed indexed literature relating to GHRH analogues, GHSR agonists, and pulsatile growth hormone secretion in human research.
Research Use Only Disclaimer
BioPepTech products are supplied strictly for research use only. They are not intended for human consumption and are not intended to diagnose, treat, cure, or prevent disease.
